EWのチャート
EWの企業情報
| symbol | EW |
|---|---|
| 会社名 | Edwards Lifesciences Corp （EW エドワ―ズライフサイエンス） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 エドワーズ・ライフサイエンス(Edwards Lifesciences Corporation)は欠陥心臓弁の置換、または修復に応用する心臓弁システムおよび修復製品の製造者である。同社は構造的心疾患および重症ケアのモニタリングなどの患者中心のイノベーションに従事する。同社のセグメントは米国、ヨーロッパ、日本、他の地域を含む。同社の製品分野は外科心臓弁療法、経カテーテル心臓弁、およびクリティカルケアを含む。同社は入院中の患者の心臓血管機能を測定するために使用される血行動態モニタリングシステムを提供する。同社の経カテーテル心臓弁製品は米国、シンガポール、スイスに生産される。クリティカルケア製品はプエルトリコとドミニカ共和国にある施設で生産される。同社の子会社はEdwards Lifesciences Asset Management Corporation、Edwards Lifesciences CardiAQ LLC.、 Valtech Cardio Inc.とRed Hill Insurance Corporationを含む。 エドワ―ズ・ライフサイエンスは重度の循環器疾患治療用の医療器具メ―カ―。心臓弁膜症などの循環器疾患や心臓血管疾患、また、救命救急診療技術、抹消血管障害の治療に焦点を置く。主要製品は、弁膜症治療用心臓弁｢カ―ペンタ―・エドワ―ズ・ペリマウント｣､人工弁輪、肺動脈カテ―テルなど。製品は約100カ国で販売される。 edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life. |
| 本社所在地 | One Edwards Way Irvine CA 92614 USA |
| 代表者氏名 | Michael A. Mussallem |
| 代表者役職名 | Chairman of the Board Chief Executive Officer |
| 電話番号 | +1 949-250-2500 |
| 設立年月日 | 36404 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 12800人 |
| url | www.edwards.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 1155.80000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 39817.57000 |
| 売上高 | 売上高（百万ドル） 3722.80000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 39454.87000 |
| 当期純利益 | 当期純利益（百万ドル） 747.00000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Edwards Lifesciences Corp revenues increased 8% to $3.72B. Net income before extraordinary items decreased 16% to $738M. Revenues reflect Transcatheter Heart Valve Therapy segment increase of 13% to $2.29B Critical Care segment increase of 12% to $674.5M United States segment increase of 8% to $2.06B Rest of the world segment increase of 14% to $396M. |
EWのテクニカル分析
EWのニュース
$1000 Invested In This Stock 10 Years Ago Would Be Worth $7,400 Today 2023/06/08 20:30:51 Benzinga
Edwards Lifesciences (NYSE: EW ) has outperformed the market over the past 10 years by 11.87% on an annualized basis producing an average annual return of 22.12%. Currently, Edwards Lifesciences has a market capitalization of $50.90 billion. Buying $1000 In EW: If … Full story available on Benzinga.com
Illumina names Hologic CEO as chair, elects Edwards CFO to board 2023/06/02 14:32:37 Seeking Alpha
Illumina''s (ILMN) board has elected Hologic (HOLX) CEO Stephen MacMillan as its new non-executive chair and Edwards Lifesciences (EW) CFO Scott Ullem as an independent director.
Hemodynamic Monitoring Systems Market to Reach Revenue of US$ 2.2 Billion by 2031: Data Analysis by Experts at Transparency Market Research Inc 2023/06/01 13:33:00 Accesswire
WILMINGTON, DE / ACCESSWIRE / June 1, 2023 / Transparency Market Research Inc. - The Global Hemodynamic Monitoring Market was valued at US$ 1.2 Bn in 2021 and is projected to surpass US$ 2.2 Bn by 2031, expanding at a CAGR of 5.8% between 2022 and 2031. Increase in the elderly population, rise in prevalence of chronic illnesses, and surge in demand for upgraded monitoring systems are projected to boost the global hemodynamic monitoring systems market. Additionally, increase in healthcare spending and rise in awareness about the benefits of hemodynamic monitoring are anticipated to fuel market demand. The global industry is projected to benefit significantly from technical breakthroughs in hemodynamic monitoring equipment. Development of wireless, non-intrusive monitoring systems, and integration of AI and ML technologies, is the major focus of manufacturers. Remote monitoring as well as telemedicine have gained popularity due to the COVID-19 pandemic, which is expected to fuel the expansion of the hemodynamic monitoring system market in the near future.
China TAVR & TMV Market Report 2023: Decline in Prices of Transcatheter Mitral Valve Procedures Presents Opportunities 2023/05/30 21:45:00 Kwhen Finance
$100 Invested In This Stock 10 Years Ago Would Be Worth $800 Today 2023/05/24 20:30:55 Benzinga
Edwards Lifesciences (NYSE: EW ) has outperformed the market over the past 10 years by 13.2% on an annualized basis producing an average annual return of 22.67%. Currently, Edwards Lifesciences has a market capitalization of $50.82 billion. Buying $100 In EW: If … Full story available on Benzinga.com
Can you now get a good deal on Edwards Lifesciences Corporation’s shares? 2022/09/30 12:32:00 US Post News
The share price of Edwards Lifesciences Corporation (NYSE:EW) fell to $83.83 per share on Thursday from $84.24. While Edwards Lifesciences Corporation has underperformed by -0.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EW fell by -26.15%, with highs and lows ranging from $131.73 to $81.87, […]
Edwards Lifesciences Corporatio – Consensus Indicates Potential 38.9% Upside 2022/09/28 12:10:01 DirectorsTalk
Edwards Lifesciences Corporatio found using ticker (EW) now have 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 130 and 97 with a mean TP of 116.11. Given that the stocks previous close was at 83.59 this would indicate that there is a potential upside of 38.9%. The day 50 moving average is 96.99 while the 200 day moving average is 105.96. The market capitalisation for the company is $51,065m. Company Website: https://www.edwards.com [stock_market_widget type="chart" template="basic" color="green" assets="EW" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $70,931m based on the market concensus. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
How is EW’s stock performing after recent trades? 2022/09/22 16:40:00 US Post News
Currently, Edwards Lifesciences Corporation’s (EW) stock is trading at $84.44, marking a fall of -0.92% from last night’s close. At this price, the stock is -35.90% below its 52-week high of $131.73 and -0.87% above its 52-week low of $85.18. Based on the past 30-day period, the stock price is -14.38% below the high and […]
Edwards Lifesciences Corporatio – Consensus Indicates Potential 31.0% Upside 2022/09/21 09:08:47 DirectorsTalk
Edwards Lifesciences Corporatio found using ticker (EW) have now 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 130 and 97 and has a mean target at 116.39. Given that the stocks previous close was at 88.83 this is indicating there is a potential upside of 31.0%. There is a 50 day moving average of 98.01 and the 200 moving average now moves to 106.55. The market capitalisation for the company is $54,053m. You can visit the company''s website by visiting: https://www.edwards.com [stock_market_widget type="chart" template="basic" color="green" assets="EW" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $70,823m based on the market concensus. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Tuesday’s Top Analyst Upgrades and Downgrades: Adobe, Huntsman, Kraft Heinz, NCR, Peloton, Take-Two and Many More 2022/09/20 12:59:21 24/7 Wall street
Tuesday''s top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup, Take-Two Interactive Software and UDR.
Capital Counsel Llc Buys Edwards Lifesciences Corp, Amazon. ... 2022/02/16 22:38:44 GuruFocus
Related Stocks: EW , AMZN , EFX , VNT , HON , TSLA , KD ,
Was The Smart Money Right About Edwards Lifesciences Corporation (EW)? 2022/02/04 04:12:34 Insider Monkey
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Edwards Lifesciences upgraded at UBS on prospects in TAVR market 2022/02/02 17:33:12 Seeking Alpha
Following a decline of more than 15% in January, Edwards Lifesciences (EW) has bounced back after UBS upgraded the cardiac equipment company to Buy from Neutral, citing its potential in
Vascular Access Devices Market is Expected to Surge at a Significant CAGR of 6.64% and is also Contemplated to Reach Upto USD 6.13 Billion by 2026, Estimates DelveInsight 2022/01/27 18:00:00 Benzinga
Las Vegas, USA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Vascular Access Devices Market is Expected to Surge at a Significant CAGR of 6.64% and is also Contemplated to Reach Upto USD 6.13 Billion by 2026, Estimates DelveInsight The Vascular Access Device market is anticipated to grow tremendously in the coming years due to many factors which include the rising prevalence of end-stage renal diseases and the rising number of vascular access surgeries, these are striving the Vascular Access Devices demand, thus driving the growth of Vascular Access Device market. DelveInsight''s Vascular Access Devices Market Insights and Forecast report provides the current and forecast Vascular Access Devices, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Vascular Access Devices. Some of the essential takeaways from the Vascular Access Devices Market report: According to DelveInsight analysis, North America is expected to dominate the overall Vascular Access Devices Market during the forecast period.